Monday, 28 May 2018

You are here

Rheumatic IRAEs Gaining Speed

Today I was fortunate to be a part of a From Bench to Bedside session on the topic of controlling the balance between cancer and autoimmunity, chaired by Drs. Leonard Calabrese and Xavier Mariette. Rheumatic IRAEs from checkpoint inhibitor therapy are growing rapidly in scope and rheumatologists must be aware of these complications, as they are certain to encounter this type of patient.

The first talk was by Dr. Antony Rosen (JHU) who discussed possible mechanisms underlying cancer in the setting of autoimmune disease, focusing on the strong associated between RNA pol III positive systemic sclerosis and the development of cancer. Next up was Dr. Aurélien Marabelle (France) who spoke from the oncology perspective on the paradigm shift in cancer therapy from drugs that target cancers to these checkpoint inhibitors that target the patient’s own immune system. He stressed the importance of interprofessional care of these patients by oncology and rheumatology.

I was thrilled to present the first abstract on our Cleveland Clinic experience with rheumatic IRAEs thus far. In our experience it seems that rheumatic IRAEs may not be self-limiting like some of the other system IRAEs (skin, gut), but rather here to stay, making the role of the rheumatologist all the more important. Dr. Rakiba Belkhir (Paris) presented the final abstract and shared a case series of 6 patients who developed ACPA-positive RA on checkpoint therapy.

Tak away points stressed that rheumatologists must become familiar with rheumatic IRAEs and engage with oncologists inter-professionally to optimize patient care, as their frequency will continue to increase.

Add new comment

More Like This

The RheumNow Week in Review – Methotrexate CIRT Study (5.25.18)

Dr. Jack Cush reviews this past week's news from - the risk of Cutaneous and Systemic LE, increasing flu vaccination, higher risk of VTE, MPO predictions, new drug for GIOP and CIRT - MTX in cardiovascular risk patients.

ACR Leaders Lobby Capitol Hill for Help on Rising Costs and Access Barriers in Arthritis Care

Rheumatologists and rheumatology health professionals convened on Capitol Hill this week to urge legislative action on pressing policy issues affecting rheumatology care during the American College of Rheumatology’s Advocacy Leadership Conference, held May 16 -17, 2018 in Washington, D.C.

The RheumNow Week in Review – Modifiable Behavior (5.18.18)

Dr. Jack Cush reviews the news and journal articles from the past week on  He discusses opioids, new approval for polyarticular JIA, running and osteoarthritis, and modifiable behaviors that influence outcomes. 

The RheumNow Week in Review - Nonadherence and Astronomic Costs (5.11.18)

Dr. Jack Cush reviews highlights, news and journal articles from the past week on

Rising Need for Weight Loss Counseling in Arthritic Patients

The CDC's May 4th MMWR reports that from 2002 to 2014, the prevalence of health care provider counseling for weight loss among adults with arthritis and overweight or obesity increased by 10% (from 35% to 45%).

Among the 54.4 million adults with doctor-diagnosed arthritis in the United States, 32.7% are overweight and 38.1% are obese. Moreover obesity is more prevalent among persons with arthritis than among those who do not have arthritis.